Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression By Ogkologos - July 16, 2025 666 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATRACTIB study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Majority of Patients With Cancer Are Willing To Be Vaccinated Against... February 2, 2021 Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR... November 3, 2023 Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC... September 23, 2025 FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated... October 13, 2022 Load more HOT NEWS Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function... What to Know About Nonalcoholic Fatty Liver Disease (NAFLD) and Its... Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type... Enhertu May Be Preferred Therapy for Some Metastatic Breast Cancers
